Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.68 EUR | -1.75% | -0.59% | -36.84% |
Apr. 08 | Advicenne S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 25 | Advicenne: ODD designation in cystinuria | CF |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 71.17 | 84.19 | 94.11 | 45.4 | 32.68 | 20.63 | - |
Enterprise Value (EV) 1 | 54.99 | 81.21 | 93.96 | 55.83 | 32.68 | 43.33 | 17.43 |
P/E ratio | -5.06 x | -5.68 x | -7.1 x | -3.94 x | -3.97 x | -2.63 x | 0.82 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | 27.5 x | 23.6 x | 28.5 x | 19.4 x | 11.1 x | 4.91 x | 3.59 x |
EV / Revenue | 21.3 x | 22.8 x | 28.5 x | 23.8 x | 11.1 x | 10.3 x | 3.03 x |
EV / EBITDA | -4.01 x | -5.83 x | -7.82 x | -5.74 x | -5.23 x | -7.34 x | 0.65 x |
EV / FCF | -5.28 x | - | - | -6.03 x | - | -4.33 x | 0.83 x |
FCF Yield | -18.9% | - | - | -16.6% | - | -23.1% | 120% |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 8,088 | 8,419 | 9,885 | 9,934 | 12,287 | 12,283 | - |
Reference price 2 | 8.800 | 10.00 | 9.520 | 4.570 | 2.660 | 1.680 | 1.680 |
Announcement Date | 3/13/20 | 4/28/21 | 3/31/22 | 3/30/23 | 3/28/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net sales 1 | 2.584 | 3.564 | 3.3 | 2.341 | 2.942 | 4.2 | 5.75 |
EBITDA 1 | -13.71 | -13.92 | -12.02 | -9.725 | -6.246 | -5.9 | 26.75 |
EBIT 1 | -14.25 | -14.14 | -12.44 | -10.06 | -6.457 | -6.3 | 10.3 |
Operating Margin | -551.39% | -396.63% | -377.09% | -429.69% | -219.48% | -150% | 179.13% |
Earnings before Tax (EBT) | - | - | - | - | - | - | - |
Net income 1 | -13.71 | -14.85 | -12.43 | -11.47 | -7.031 | -7.9 | 22.3 |
Net margin | -530.75% | -416.55% | -376.58% | -489.96% | -238.99% | -188.1% | 387.83% |
EPS 2 | -1.740 | -1.760 | -1.340 | -1.160 | -0.6700 | -0.6400 | 2.060 |
Free Cash Flow 1 | -10.41 | - | - | -9.262 | - | -10 | 20.95 |
FCF margin | -402.86% | - | - | -395.64% | - | -238.1% | 364.35% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | 78.32% |
FCF Conversion (Net income) | - | - | - | - | - | - | 93.95% |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 3/13/20 | 4/28/21 | 3/31/22 | 3/30/23 | 3/28/24 | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | 10.4 | - | 22.7 | - |
Net Cash position 1 | 16.2 | 2.97 | 0.15 | - | - | - | 3.2 |
Leverage (Debt/EBITDA) | - | - | - | -1.072 x | - | -3.847 x | - |
Free Cash Flow 1 | -10.4 | - | - | -9.26 | - | -10 | 21 |
ROE (net income / shareholders' equity) | -58.9% | - | -694% | - | - | - | 372% |
ROA (Net income/ Total Assets) | - | - | - | - | - | 61.3% | 177% |
Assets 1 | - | - | - | - | - | -12.89 | 12.6 |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | 0.93 | - | - | 0.12 | - | 1 | 0.75 |
Capex / Sales | 35.99% | - | - | 4.91% | - | 23.81% | 13.04% |
Announcement Date | 3/13/20 | 4/28/21 | 3/31/22 | 3/30/23 | 3/28/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-36.84% | 22.03M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- ALDVI Stock
- Financials Advicenne